Sun Pharma Q4 results: Consolidated net profit declines 37% to Rs 399 cr; revenue up 14% to Rs 8,185 cr

Pharma major Sun Pharmaceutical Industries on Wednesday reported a 37.12 percent decline in its consolidated net profit to Rs 399.84 crore for the quarter ended March 2020, mainly on account of one time exceptional loss

Press Trust of India May 27, 2020 17:48:04 IST
Sun Pharma Q4 results: Consolidated net profit declines 37% to Rs 399 cr; revenue up 14% to Rs 8,185 cr

New Delhi: Pharma major Sun Pharmaceutical Industries on Wednesday reported a 37.12 percent decline in its consolidated net profit to Rs 399.84 crore for the quarter ended March 2020, mainly on account of one time exceptional loss.

The company had posted a net profit of Rs 635.88 crore in the same period previous fiscal, Sun Pharma said in a BSE filing.

Consolidated revenue from operations stood at Rs 8,184.94 crore for the quarter under consideration as against Rs 7,163.92 crore in the same period a year ago, it added.

The company had a one-time exceptional loss of Rs 260.64 crore in the quarter ended March 2020, the filing said.

For the fiscal ended March 2020, the net profit of the company was at Rs 3,764.93 crore as against Rs 2,665.42 crore in the previous fiscal, Sun Pharma said.

The revenue from operations for the fiscal ended March this year stood at Rs 32,837.50 crore. It was Rs 29,065.91 crore the year-ago fiscal, it added.

The board has recommended payment of a dividend of Re 1 per equity share of Re 1 each for the year ended 31 March, 2020, Sun Pharma said.

Shares of Sun Pharmaceutical Industries were closed at Rs 450.55 per scrip on the BSE, down 1.85 percent from its previous close.

Updated Date:

also read

Sun Pharma Q3 net profit declines 27% to Rs 914 cr; consolidated income rises 5% to Rs 8,039 cr
Business

Sun Pharma Q3 net profit declines 27% to Rs 914 cr; consolidated income rises 5% to Rs 8,039 cr

Drug major Sun Pharmaceutical Industries on Thursday reported a 26.43 percent decline in its consolidated net profit to Rs 913.52 crore for the quarter ended 31 December, 2019 mainly due to rise in expenses

Sun Pharma arm gets relief from US court in patent infringement case
Business

Sun Pharma arm gets relief from US court in patent infringement case

Massachusetts-based DUSA has been granted preliminary injunctive relief by a federal district court prohibiting defendants Biofrontera Inc, Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, and Biofrontera AGf from using its confidential and proprietary trade secret information, Sun Pharmaceutical Industries said

Why Stan Chart sees upside in ACC Cement, Idea
Investing

Why Stan Chart sees upside in ACC Cement, Idea

Banking major Standard Chartered has said that stocks of Indian companies has seen an upheaval in the recent past due to irrational fears and stocks being pummelled multiple times for the same news.